{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T04:08:03Z","timestamp":1747454883493,"version":"3.40.5"},"reference-count":22,"publisher":"Sociedade Brasileira de Cardiologia","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,15]]},"DOI":"10.36660\/abc.20210832","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T12:51:08Z","timestamp":1645015868000},"page":"378-387","source":"Crossref","is-referenced-by-count":0,"title":["Justificativa e Desenho do Ensaio Cl\u00ednico Randomizado COVID-19 Outpatient Prevention Evaluation (COPE - Coalition V): Hidroxicloroquina vs. Placebo em Pacientes N\u00e3o Hospitalizados"],"prefix":"10.36660","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0289-4947","authenticated-orcid":false,"suffix":"Junior","given":"Haliton Alves de","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cleusa P.","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Icaro","family":"Boszczowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1815-6498","authenticated-orcid":false,"given":"Gustavo B. F.","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre B.","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regis G.","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luciano C. P.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane C.","family":"Veiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otavio","family":"Berwanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Avezum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22636","reference":[{"key":"key20220216075100_B1","article-title":"Clinical Findings in a Group of Patients Infected with the 2019 Novel Coronavirus (SARS-Cov-2) Outside of Wuhan, China: Retrospective Case Series","volume":"368","author":"Xu","year":"2020","unstructured":"1. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical Findings in a Group of Patients Infected with the 2019 Novel Coronavirus (SARS-Cov-2) Outside of Wuhan, China: Retrospective Case Series. BMJ. 2020;368:m606. doi: 10.1136\/bmj.m606.","journal-title":"BMJ"},{"key":"key20220216075100_B2","author":"World Health Organization","year":"2020","unstructured":"2. World Health Organization. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection is Suspected. Geneva: WHO Library; 2020.","journal-title":"Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (nCoV) Infection is Suspected"},{"issue":"10223","key":"key20220216075100_B3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","unstructured":"3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: 10.1016\/S0140-6736(20)30183-5.","journal-title":"Lancet"},{"issue":"5","key":"key20220216075100_B4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00392-020-01626-9","article-title":"Prevalence and Impact of Cardiovascular Metabolic Diseases on COVID-19 in China","volume":"109","author":"Li","year":"2020","unstructured":"4. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and Impact of Cardiovascular Metabolic Diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531-38. doi: 10.1007\/s00392-020-01626-9.","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"key20220216075100_B5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamainternmed.2020.6319","article-title":"Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial","volume":"181","author":"Abella","year":"2021","unstructured":"5. Abella BS, Jolkovsky EL, Biney BT, Uspal JE, Hyman MC, Frank I, et al. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial. JAMA Intern Med. 2021;181(2):195-202. doi: 10.1001\/jamainternmed.2020.6319.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"key20220216075100_B6","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/cid\/ciaa1571","article-title":"Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial","volume":"72","author":"Rajasingham","year":"2021","unstructured":"6. Rajasingham R, Bangdiwala AS, Nicol MR, Skipper CP, Pastick KA, Axelrod ML, et al. Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. Clin Infect Dis. 2021;72(11):835-43. doi: 10.1093\/cid\/ciaa1571.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"key20220216075100_B7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7326\/M20-6519","article-title":"Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial","volume":"174","author":"Barnabas","year":"2021","unstructured":"7. Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, et al. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Randomized Trial. Ann Intern Med. 2021 Mar;174(3):344-52. doi: 10.7326\/M20-6519.","journal-title":"Ann Intern Med"},{"issue":"6","key":"key20220216075100_B8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19","volume":"383","author":"Boulware","year":"2020","unstructured":"8. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020;383(6):517-25. doi: 10.1056\/NEJMoa2016638.","journal-title":"N Engl J Med"},{"issue":"5","key":"key20220216075100_B9","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa2021801","article-title":"A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19","volume":"384","author":"Mitj\u00e0","year":"2021","unstructured":"9. Mitj\u00e0 O, Corbacho-Monn\u00e9 M, Ubals M, Alemany A, Su\u00f1er C, Teb\u00e9 C, et al. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19. N Engl J Med. 2021;384(5):417-27. doi: 10.1056\/NEJMoa2021801.","journal-title":"N Engl J Med"},{"issue":"11","key":"key20220216075100_B10","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1093\/cid\/ciaa1009","article-title":"Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial","volume":"73","author":"Mitj\u00e0","year":"2021","unstructured":"10. Mitj\u00e0 O, Corbacho-Monn\u00e9 M, Ubals M, Teb\u00e9 C, Pe\u00f1afiel J, Tobias A, et al. Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. Clin Infect Dis. 2021;73(11):4073-81. doi: 10.1093\/cid\/ciaa1009.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"key20220216075100_B11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.7326\/M20-4207","article-title":"Hydroxychloroquine in Nonhospitalized Adults with Early COVID-19: A Randomized Trial","volume":"173","author":"Skipper","year":"2020","unstructured":"11. Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, et al. Hydroxychloroquine in Nonhospitalized Adults with Early COVID-19: A Randomized Trial. Ann Intern Med. 2020;173(8):623-31. doi: 10.7326\/M20-4207.","journal-title":"Ann Intern Med"},{"key":"key20220216075100_B12","article-title":"Randomized Double-Blinded Placebo-Controlled Trial of Hydroxychloroquine with or without Azithromycin for Virologic Cure of Non-Severe COVID-19","volume":"29","author":"Omrani","year":"2020","unstructured":"12. Omrani AS, Pathan SA, Thomas SA, Harris TRE, Coyle PV, Thomas CE, et al. Randomized Double-Blinded Placebo-Controlled Trial of Hydroxychloroquine with or without Azithromycin for Virologic Cure of Non-Severe COVID-19. EClinicalMedicine. 2020;29:100645. doi: 10.1016\/j.eclinm.2020.100645.","journal-title":"EClinicalMedicine"},{"key":"key20220216075100_B13","author":"Brasil","year":"2020","unstructured":"13. Brasil. Minist\u00e9rio da Sa\u00fade. Diretrizes para Diagn\u00f3stico e Tratamento da COVID-19 (Clinical Guideline Covid-19) [Internet]. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade. 2020 [cited 2021 Mar 18]. Available from: https:\/\/portaldeboaspraticas.iff.fiocruz.br\/atencao-mulher\/diretrizes-para-diagnostico-e-tratamento-da-covid-19-ms\/.","journal-title":"Diretrizes para Diagn\u00f3stico e Tratamento da COVID-19 (Clinical Guideline Covid-19)"},{"key":"key20220216075100_B14","author":"World Health Organization","year":"2021","unstructured":"14. World Health Organization. Country & Technical Guidance - Coronavirus Disease (COVID-19) [Internet]. Geneva: WHO. 2021 [cited 2021 Mar 18]. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/technical-guidance.","journal-title":"Country & Technical Guidance - Coronavirus Disease (COVID-19)"},{"issue":"5","key":"key20220216075100_B15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.36660\/abc.20200279","article-title":"The Heart and COVID-19: What Cardiologists Need to Know","volume":"114","author":"Costa","year":"2020","unstructured":"15. Costa IBSDS, Bittar CS, Rizk SI, Ara\u00fajo Filho AE, Santos KAQ, Machado TIV, et al. The Heart and COVID-19: What Cardiologists Need to Know. Arq Bras Cardiol. 2020;114(5):805-16. doi: 10.36660\/abc.20200279.","journal-title":"Arq Bras Cardiol"},{"key":"key20220216075100_B16","doi-asserted-by":"crossref","DOI":"10.1002\/9781118439241","volume-title":"Sample Size Determination and Power","author":"Ryan","year":"2013","unstructured":"16. Ryan TP. Sample Size Determination and Power. New Jersey: Wiley; 2013."},{"key":"key20220216075100_B17","volume-title":"Sample Size Calculations in Clinical Research, Second Edition (Chapman & Hall\/CRC Biostatistics Series)","author":"Shein-Chung","year":"2008","unstructured":"17. Shein-Chung C, Wang JSH. Sample Size Calculations in Clinical Research, Second Edition (Chapman & Hall\/CRC Biostatistics Series). 2nd ed. Boca Raton: Chapman & Hall\/CRC Biostatistics Series; 2008.","edition":"2nd"},{"issue":"4","key":"key20220216075100_B18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0197-2456(88)90049-9","article-title":"Randomization in Clinical Trials: Conclusions and Recommendations","volume":"9","author":"Lachin","year":"1988","unstructured":"18. Lachin JM, Matts JP, Wei LJ. Randomization in Clinical Trials: Conclusions and Recommendations. Control Clin Trials. 1988;9(4):365-74. doi: 10.1016\/0197-2456(88)90049-9.","journal-title":"Control Clin Trials"},{"issue":"526","key":"key20220216075100_B19","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1259\/0007-1285-44-526-793","article-title":"Repeated Assessment of Results in Clinical Trials of Cancer Treatment","volume":"44","author":"Haybittle","year":"1971","unstructured":"19. Haybittle JL. Repeated Assessment of Results in Clinical Trials of Cancer Treatment. Br J Radiol. 1971;44(526):793-7. doi: 10.1259\/0007-1285-44-526-793.","journal-title":"Br J Radiol"},{"issue":"2","key":"key20220216075100_B20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1740774518823551","article-title":"Assessing the Impact of Efficacy Stopping Rules on the Error Rates Under the Multi-Arm Multi-Stage Framework","volume":"16","author":"Blenkinsop","year":"2019","unstructured":"20. Blenkinsop A, Parmar MK, Choodari-Oskooei B. Assessing the Impact of Efficacy Stopping Rules on the Error Rates Under the Multi-Arm Multi-Stage Framework. Clin Trials. 2019;16(2):132-41. doi: 10.1177\/1740774518823551.","journal-title":"Clin Trials"},{"key":"key20220216075100_B21","doi-asserted-by":"crossref","DOI":"10.1201\/9781315154275","volume-title":"Multiple Imputation in Practice: With Examples Using IVEware","author":"Raghunathan","year":"2018","unstructured":"21. Raghunathan T, Berglund PA, Solenberger PW. Multiple Imputation in Practice: With Examples Using IVEware. Milton Park: Taylor & Francis; 2018."},{"key":"key20220216075100_B22","volume-title":"Multiple Imputation of Missing Data Using SAS","author":"Patricia Berglund SGH","year":"2014","unstructured":"22. Patricia Berglund SGH. Multiple Imputation of Missing Data Using SAS. Cary: SAS Institute; 2014."}],"container-title":["Arquivos Brasileiros de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/abccardiol.org\/article\/justificativa-e-desenho-do-ensaio-clinico-randomizado-covid-19-outpatient-prevention-evaluation-cope-coalition-v-hidroxicloroquina-vs-placebo-em-pacientes-nao-hospitalizados\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:07:59Z","timestamp":1747400879000},"score":1,"resource":{"primary":{"URL":"https:\/\/abccardiol.org\/article\/justificativa-e-desenho-do-ensaio-clinico-randomizado-covid-19-outpatient-prevention-evaluation-cope-coalition-v-hidroxicloroquina-vs-placebo-em-pacientes-nao-hospitalizados\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,15]]}},"alternative-id":["10.36660\/abc.20210832"],"URL":"https:\/\/doi.org\/10.36660\/abc.20210832","relation":{},"ISSN":["0066-782X","1678-4170"],"issn-type":[{"type":"print","value":"0066-782X"},{"type":"electronic","value":"1678-4170"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}